The Medical Advisor

Dimethyl sulfoxide (DMSO) is one of the more unusual compounds in medicine. It has anti-inflammatory, analgesic, membrane-active, antioxidant and drug-delivery properties, and decades of laboratory research have examined its effects on platelets, vascular tone, ischemia, tissue injury and the blood-brain barrier. These properties have generated a provocative hypothesis: could DMSO improve circulation, reduce vascular injury and protect tissue during ischemic events such as stroke? The hypothesis is biologically plausible, but the clinical evidence is much less definitive than some popular accounts suggest. DMSO has demonstrated important vascular and neuroprotective effects in laboratory and experimental models, while human evidence remains limited and insufficient to establish DMSO as a standard treatment for acute stroke, myocardial infarction, deep-vein thrombosis or peripheral arterial disease. Clinical bottom line: DMSO should currently be regarded as an investigational o...

Mebendazole is an established antiparasitic medicine that has attracted attention as a potential repurposed cancer drug. Laboratory studies and animal models have reported anticancer activity, while a small number of published human cases and early clinical trials have generated interest. Important: Mebendazole is not an established cancer treatment and should not be substituted for evidence-based oncology care. Some human studies are encouraging, while others have produced limited or inconclusive results. The strongest interpretation of the evidence is that mebendazole remains an investigational repurposing candidate , not a proven cancer cure. This 2026 update reviews the evidence behind commonly cited “ mebendazole cancer success stories ,” including published human case reports, randomized and early-phase clinical studies, preclinical research, and the limitations of anecdotal reports. Editorial update: September 2026 ...

Updated: September 2026 GLP-1 medicines have moved from being primarily diabetes treatments to becoming a major platform for obesity and cardiometabolic medicine. The strongest clinical-trial evidence now extends beyond weight loss to cardiovascular disease, chronic kidney disease, heart failure, metabolic liver disease and other obesity-related complications.   But "GLP-1" is not one drug, and the studies are not interchangeable. Semaglutide, tirzepatide, liraglutide and newer investigational medicines act on overlapping but different metabolic pathways, and the populations, doses and outcomes studied vary substantially. Key takeaway: The most important GLP-1 evidence through 2026 falls into several categories: weight loss, cardiovascular outcomes, kidney outcomes, heart failure, metabolic liver disease, diabetes control, long-term weight maintenance and next-generation multi-receptor drugs. The strongest conclusions come from randomized controlled trials with c...